Fibrinogen catabolism in systemic lupus erythematosus

John S. Sergent, Raymond L. Sherman, Hamid Al‐Mondhiry

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Because there is mounting evidence that localized intravascular coagulation maycontribute to tissue injury following a variety of immunologic events, including immune complex diseases, fibrinogen catabolism was studied in patients with systemic lupus erythematosus to determine factors correlating with accelerated coagulation. 125I‐fibrinogen half‐life in controls was 80.1 ± 11 hours and the mean SLE half‐life was 60.5 ± 12. SLE patients in complete clinical remission had normal half‐lives, but patients with symptomatic clinical disease, including renal disease, had significantly reduced fibrinogen survival. Accelerated fibrinogen consumption also correlated with positive tests for anti‐DNA antibodies, but not with hypocomplementemia. These observations support the hypothesis that the coagulation system is activated in patients with immune complex diseases. Further studies are required to define the role, if any, that coagulation may play in causing tissue injury.

Original languageEnglish (US)
Pages (from-to)195-198
Number of pages4
JournalArthritis & Rheumatism
Volume19
Issue number2
DOIs
StatePublished - Jan 1 1976

Fingerprint

Systemic Lupus Erythematosus
Fibrinogen
Immune Complex Diseases
Half-Life
Wounds and Injuries
Kidney
Antibodies

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Sergent, J. S., Sherman, R. L., & Al‐Mondhiry, H. (1976). Fibrinogen catabolism in systemic lupus erythematosus. Arthritis & Rheumatism, 19(2), 195-198. https://doi.org/10.1002/art.1780190211
Sergent, John S. ; Sherman, Raymond L. ; Al‐Mondhiry, Hamid. / Fibrinogen catabolism in systemic lupus erythematosus. In: Arthritis & Rheumatism. 1976 ; Vol. 19, No. 2. pp. 195-198.
@article{e3a45ad60494480b9c815a1f6ce1ba40,
title = "Fibrinogen catabolism in systemic lupus erythematosus",
abstract = "Because there is mounting evidence that localized intravascular coagulation maycontribute to tissue injury following a variety of immunologic events, including immune complex diseases, fibrinogen catabolism was studied in patients with systemic lupus erythematosus to determine factors correlating with accelerated coagulation. 125I‐fibrinogen half‐life in controls was 80.1 ± 11 hours and the mean SLE half‐life was 60.5 ± 12. SLE patients in complete clinical remission had normal half‐lives, but patients with symptomatic clinical disease, including renal disease, had significantly reduced fibrinogen survival. Accelerated fibrinogen consumption also correlated with positive tests for anti‐DNA antibodies, but not with hypocomplementemia. These observations support the hypothesis that the coagulation system is activated in patients with immune complex diseases. Further studies are required to define the role, if any, that coagulation may play in causing tissue injury.",
author = "Sergent, {John S.} and Sherman, {Raymond L.} and Hamid Al‐Mondhiry",
year = "1976",
month = "1",
day = "1",
doi = "10.1002/art.1780190211",
language = "English (US)",
volume = "19",
pages = "195--198",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

Sergent, JS, Sherman, RL & Al‐Mondhiry, H 1976, 'Fibrinogen catabolism in systemic lupus erythematosus', Arthritis & Rheumatism, vol. 19, no. 2, pp. 195-198. https://doi.org/10.1002/art.1780190211

Fibrinogen catabolism in systemic lupus erythematosus. / Sergent, John S.; Sherman, Raymond L.; Al‐Mondhiry, Hamid.

In: Arthritis & Rheumatism, Vol. 19, No. 2, 01.01.1976, p. 195-198.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fibrinogen catabolism in systemic lupus erythematosus

AU - Sergent, John S.

AU - Sherman, Raymond L.

AU - Al‐Mondhiry, Hamid

PY - 1976/1/1

Y1 - 1976/1/1

N2 - Because there is mounting evidence that localized intravascular coagulation maycontribute to tissue injury following a variety of immunologic events, including immune complex diseases, fibrinogen catabolism was studied in patients with systemic lupus erythematosus to determine factors correlating with accelerated coagulation. 125I‐fibrinogen half‐life in controls was 80.1 ± 11 hours and the mean SLE half‐life was 60.5 ± 12. SLE patients in complete clinical remission had normal half‐lives, but patients with symptomatic clinical disease, including renal disease, had significantly reduced fibrinogen survival. Accelerated fibrinogen consumption also correlated with positive tests for anti‐DNA antibodies, but not with hypocomplementemia. These observations support the hypothesis that the coagulation system is activated in patients with immune complex diseases. Further studies are required to define the role, if any, that coagulation may play in causing tissue injury.

AB - Because there is mounting evidence that localized intravascular coagulation maycontribute to tissue injury following a variety of immunologic events, including immune complex diseases, fibrinogen catabolism was studied in patients with systemic lupus erythematosus to determine factors correlating with accelerated coagulation. 125I‐fibrinogen half‐life in controls was 80.1 ± 11 hours and the mean SLE half‐life was 60.5 ± 12. SLE patients in complete clinical remission had normal half‐lives, but patients with symptomatic clinical disease, including renal disease, had significantly reduced fibrinogen survival. Accelerated fibrinogen consumption also correlated with positive tests for anti‐DNA antibodies, but not with hypocomplementemia. These observations support the hypothesis that the coagulation system is activated in patients with immune complex diseases. Further studies are required to define the role, if any, that coagulation may play in causing tissue injury.

UR - http://www.scopus.com/inward/record.url?scp=0016931198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016931198&partnerID=8YFLogxK

U2 - 10.1002/art.1780190211

DO - 10.1002/art.1780190211

M3 - Article

C2 - 1259800

AN - SCOPUS:0016931198

VL - 19

SP - 195

EP - 198

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 2

ER -